Put simply, chemotherapy drugs have to get inside cancer cells to kill them. Conventionally, this is achieved by using high doses of these drugs, leading to very undesirable and sometimes even fatal side effects.
One of the little known facts about cancer cells is that they make their own insulin in order to obtain glucose-the fuel they need in large amounts as they grow and divide at an abnormally rapid rate.
We take advantage of insulin’s action. By giving cancer cells insulin, we prime the membranes to open up. Coordinating this event with the introduction of low-doses of chemotherapy, we get much more of the chemotherapy drugs inside the cancer cells to kill them, leaving healthy cells unharmed. This process allows us to avoid dangerous, undesirable dose-related side effects.
Described in technical terms, Insulin Potentiation Therapy (IPT) manipulates the mechanisms of malignancy to therapeutic advantage by employing insulin as a biologic response modifier of cancer cells’ endogenous molecular biology. The autonomous proliferation of malignancy is supported by autocrine secretion of insulin for glucose/energy uptake by cancer cells, and a similar autocrine and/or paracrine elaboration of cellular factors to stimulate cancer growth. Amongst these, the insulin-like growth factors have been identified as the most potent mitogens for cancer cells. Of primary importance for the appreciation of IPT is the little known fact that cancer cell membranes have six time more insulin receptors and ten times more IGF receptors, per cell, than the membranes of host normal tissues. Further, insulin can effectively cross-react with and activate cancer cell IGF receptors. Thus, per cell, cancer cells have sixteen times more insulin-sensitive receptors than normal tissues. As ligand effect is a function of receptor concentration, these facts serve to differentiate cancer from normal cells –a vital consideration for the safety of cancer chemotherapy.
Because of its favorable side effect profile, cycles of low-dose chemotherapy with IPT may be done more frequently, usually once and sometimes twice a week. There is good patient acceptance of the mild adrenergic, hypoglycemic side effects of the protocol. The “rescue phenomenon” occasioned by the timely administration of hypertonic glucose actually serves to provide patients with an experiential metaphor for the rapid recovery of their well-being. It is acknowledged that cancer treatment can often be debilitating for patients. In those undergoing cancer treatment with IPT, an overall gentler experience promotes their concurrent involvement in other important elements of Comprehensive Cancer Care, which includes nutrition for immune system support, and mind-body medicine to support a healing consciousness.
-Insulin Potentiation Therapy Manual: Articles, Supportive Research and Case Studies-